🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,385

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

6,121 results for “ACE” Clear

  1. "myk-461 capsules, placebo is a solid oral dosage form in size 2 gelatin capsules each containing 120 mg of an excipient blend. it is intended as a placebo to match myk-461 capsules of all active strengths", Mavacamten, Mavacamten, Mavacamten, Mavacamten, Mavacamten

    Bristol-Myers Squibb / Pfizer EEIG

    Symptomatic Obstructive Hypertrophic Cardiomyopathy

    phase 3 small molecule active

    1 trial

  2. -, -, ERYTHROPOIETIN , DANAZOL , VAY736, -, ENTECAVIR , Placebo to VAY736 150 mg/1 mL concentrate for solution for infusion, -, -

    Novartis Ophthalmics Europe

    warm autoimmune haemolytic anaemia (wAIHA)

    phase 3 small molecule active

    1 trial

  3. -, -, PACLITAXEL , DOXORUBICIN HYDROCHLORIDE, LIPOSOMAL, KEYTRUDA 25 mg/mL concentrate for solution for infusion, MK-2870, MK-2870, DOXORUBICIN , CAPECITABINE , PACLITAXEL ALBUMIN-BOUND, DEXAMETHASONE , PARACETAMOL

    Merck Sharp and Dohme

    Hormone receptor positive breast cancer

    phase 3 small molecule active

    1 trial

  4. -, Apalutamide placebo, JNJ-56021927

    Janssen-Cilag International N.V.

    Metastatic Hormone-sensitive Prostate Cancer

    phase 3 small molecule active

    1 trial

  5. -, COLESTYRAMINE , AUBAGIO 14 mg film-coated tablets, -, Matched Placebo to Test, Tolebrutinib, Matched Placebo for Comparator Teriflunomide

    Sanofi Pharma Bristol-Myers Squibb

    Nervous system diseases

    phase 3 small molecule active

    1 trial

  6. -, DOCETAXEL , DEXAMETHASONE , -, -, MK-2870, PARACETAMOL, COMBINATIONS EXCL. PSYCHOLEPTICS, PEMETREXED

    Merck Sharp and Dohme

    Non-small Cell Lung Cancer (NSCLC)

    phase 3 small molecule active

    1 trial

  7. -, IRINOTECAN , PARACETAMOL , -, -, PACLITAXEL , TRIFLURIDINE, COMBINATIONS, MK-2870, DOCETAXEL

    Merck Sharp and Dohme

    advanced or metastatic gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, or esophageal adenocarcinoma

    phase 3 small molecule active

    1 trial

  8. -, KEYTRUDA 25 mg/mL concentrate for solution for infusion, -, CAPECITABINE , PARACETAMOL , MK-2870, DEXAMETHASONE

    Merck Sharp and Dohme

    Triple negative breast cancer.

    phase 3 small molecule active

    1 trial

  9. -, PARACETAMOL , CILAZAPRIL , Dapirolizumab pegol, EPINEPHRINE , DIPHENHYDRAMINE , -, -, -, -, -, -, -

    Pharma Mar S.A.

    Systemic lupus erythematosus (SLE)

    phase 3 small molecule active

    1 trial

  10. -, PARACETAMOL , MK-2870, PACLITAXEL , -, KEYTRUDA 25 mg/mL concentrate for solution for infusion, -, CARBOPLATIN , PACLITAXEL ALBUMIN-BOUND, DEXAMETHASONE

    Merck Sharp and Dohme

    Participants with treatment-naïve metastatic squamous Non-small Cell Lung Cancer (NSCLC)

    phase 3 small molecule active

    1 trial

  11. -, Placebo to ianalumab 150 mg/1 mL concentrate for solution for infusion, -, ENTECAVIR , -, ELTROMBOPAG, -, ELTROMBOPAG, ELTROMBOPAG, VAY736, -, ELTROMBOPAG

    Novartis Ophthalmics Europe

    Primary immune thrombocytopenia (ITP)

    phase 3 small molecule active

    1 trial

  12. -, TACROLIMUS , Amlitelimab, PIMECROLIMUS , Placebo, Amlitelimab

    Sanofi Pharma Bristol-Myers Squibb

    Dermatitis atopic

    phase 3 small molecule active

    1 trial

  13. 0.05% Voclosporin Ophthalmic Solution (VOS)

    Aurinia Pharmaceuticals

    Dry Eye Syndrome

    phase 3 small molecule completed

    1 trial

  14. 0.9 % w/v Sodium Chloride Injection, Reblozyl 25 mg powder for solution for injection, Reblozyl 75 mg powder for solution for injection

    Celgene Europe Limited

    Anemia associated with myeloproliferative neoplasm (MPN)-associated myelofibrosis (MF)

    phase 3 small molecule active

    1 trial

  15. 0.9% Saline, PARACETAMOL , Felzartamab, CETIRIZINE , LORATADINE , FAMOTIDINE , DIPHENHYDRAMINE , LEVOCETIRIZINE , DESLORATADINE , FEXOFENADINE , METHYLPREDNISOLONE

    Biogen Idec Ltd

    IgA nephropathy

    phase 3 small molecule active

    1 trial

  16. 0.9% Sodium Chloride, JNJ-78901563

    Janssen Pharmaceutica N.V.

    Invasive Extraintestinal Pathogenic Escherichia coli Disease

    phase 3 small molecule active

    1 trial

  17. 131I-apamistamab

    Actinium Pharmaceuticals

    Acute Leukemia

    phase 3 small molecule active

    1 trial

  18. 20 mg VEC-162

    Vanda Pharmaceuticals Netherlands B.V.

    Insomnia

    phase 3 small molecule completed

    1 trial

  19. 25 mg Ontamalimab

    Takeda Pharmaceuticals International AG

    Crohn's Disease

    phase 3 small molecule completed

    1 trial

  20. 2mg Baricitinib

    China SXT Pharmaceuticals

    Acute Ichemic Stroke

    phase 3 small molecule active

    1 trial

  21. 35 mg oral lyophilisate, 25 mg oral lyophilisate, 50 mg oral lyophilisate, VYDURA 75 mg oral lyophilisate

    Pfizer Ireland Pharmaceuticals Unlimited Company

    Acute Migraine (with or without aura)

    phase 3 small molecule active

    1 trial

  22. 5% Lidocaine patch

    China SXT Pharmaceuticals

    Herpes Zoster Pain

    phase 3 small molecule completed

    1 trial

  23. 5% cysteamine cream

    China SXT Pharmaceuticals

    Melasma

    phase 3 other completed

    1 trial

  24. 5-Fu/epirubicin/CTX following Docetaxel

    China SXT Pharmaceuticals

    Breast Cancer

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources